NASDAQ:UTHR United Therapeutics - UTHR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. $221.83 +3.82 (+1.75%) (As of 03/28/2023 11:16 AM ET) Add Compare Share Share Today's Range$218.15▼$221.8550-Day Range$212.99▼$265.9252-Week Range$173.21▼$283.09Volume123,600 shsAverage Volume544,296 shsMarket Capitalization$10.27 billionP/E Ratio14.77Dividend YieldN/APrice Target$291.55 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability United Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside32.0% Upside$291.55 Price TargetShort InterestHealthy2.89% of Shares Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.74Based on 20 Articles This WeekInsider TradingSelling Shares$46.74 M Sold Last QuarterProj. Earnings Growth10.64%From $17.95 to $19.86 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.84 out of 5 starsMedical Sector50th out of 1,002 stocksPharmaceutical Preparations Industry15th out of 488 stocks 3.3 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 8 buy ratings, no hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $291.55, United Therapeutics has a forecasted upside of 32.0% from its current price of $220.80.Amount of Analyst CoverageUnited Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.89% of the outstanding shares of United Therapeutics have been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in United Therapeutics has recently increased by 0.75%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 2.6 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for United Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 16 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $46,738,853.00 in company stock.Percentage Held by Insiders12.40% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.63% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 10.64% in the coming year, from $17.95 to $19.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 14.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.87.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 14.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.81.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About United Therapeutics (NASDAQ:UTHR) StockUnited Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.Read More Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Stock News HeadlinesMarch 28, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for United Therapeutics Co. Decreased by Jefferies Financial Group (NASDAQ:UTHR)March 27, 2023 | finance.yahoo.comHere's Why We Think United Therapeutics (NASDAQ:UTHR) Is Well Worth WatchingMarch 28, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureMarch 27, 2023 | americanbankingnews.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 8,000 Shares of StockMarch 25, 2023 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,791,680.00 in StockMarch 24, 2023 | finance.yahoo.comUnited Therapeutics (UTHR) Down 13% Since Last Earnings Report: Can It Rebound?March 24, 2023 | markets.businessinsider.comUnited Therapeutics (UTHR) Receives a Buy from JefferiesMarch 24, 2023 | americanbankingnews.comBrokerages Set United Therapeutics Co. (NASDAQ:UTHR) PT at $291.55March 28, 2023 | Press Research (Ad)Nevada Could be the Source for America's Green FutureIndustry shift towards lithium driven by green energy goalsMarch 23, 2023 | americanbankingnews.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,743,280.00 in StockMarch 18, 2023 | finance.yahoo.comUTHR Mar 2023 280.000 callMarch 18, 2023 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Coverage Initiated at StockNews.comMarch 17, 2023 | finance.yahoo.comQ4 2022 Liquidia Corp Earnings CallMarch 10, 2023 | bizjournals.comRockville biotech Shuttle Pharmaceuticals inks deal to advance key experimental drugMarch 6, 2023 | finance.yahoo.comUnited Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 28, 2023 | businesswire.comUnited Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care ConferenceFebruary 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Bausch + Lomb Corporation (BLCO)February 23, 2023 | finance.yahoo.comUnited Therapeutics Full Year 2022 Earnings: Misses ExpectationsFebruary 22, 2023 | bizjournals.comSilver Spring's United Therapeutics posted record results last year. Here's how it plans to top that.February 22, 2023 | msn.comUnited Therapeutics GAAP EPS of $2.67 misses by $1.83, revenue of $491.5M misses by $27.7MFebruary 22, 2023 | msn.comUnited Therapeutics (UTHR) Q4 Earnings and Revenues Miss EstimatesFebruary 22, 2023 | businesswire.comUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial ResultsFebruary 21, 2023 | finance.yahoo.comShould You Buy United Therapeutics (UTHR) Ahead of Earnings?February 16, 2023 | nasdaq.comAvoro Capital Advisors Now Owns 6.30% of United Therapeutics (UTHR)February 16, 2023 | finance.yahoo.comAnalysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out forFebruary 15, 2023 | finance.yahoo.comUnited Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023February 5, 2023 | finance.yahoo.comDecision moves Liquidia, United Therapeutics patent dispute toward resolutionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Company Calendar Last Earnings2/22/2023Today3/28/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees965Year Founded1996Price Target and Rating Average Stock Price Forecast$291.55 High Stock Price Forecast$375.00 Low Stock Price Forecast$230.00 Forecasted Upside/Downside+33.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$15.02 Trailing P/E Ratio14.51 Forward P/E Ratio12.15 P/E GrowthN/ANet Income$727.30 million Net Margins37.56% Pretax Margin49.09% Return on Equity16.30% Return on Assets12.80% Debt Debt-to-Equity Ratio0.17 Current Ratio9.85 Quick Ratio9.55 Sales & Book Value Annual Sales$1.94 billion Price / Sales5.21 Cash Flow$16.93 per share Price / Cash Flow12.88 Book Value$105.24 per share Price / Book2.07Miscellaneous Outstanding Shares46,300,000Free Float40,561,000Market Cap$10.09 billion OptionableOptionable Beta0.62 Social Links Key ExecutivesMartine A. RothblattChairman & Chief Executive OfficerMichael Ian BenkowitzPresident & Chief Operating OfficerJames Christopher EdgemondTreasurer, Chief Financial & Accounting OfficerPaul A. MahonSecretary, Executive VP & General CounselDewey SteadmanHead-Investor RelationsKey CompetitorsIonis PharmaceuticalsNASDAQ:IONSAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLAmicus TherapeuticsNASDAQ:FOLDBioMarin PharmaceuticalNASDAQ:BMRNView All CompetitorsInsiders & InstitutionsMartine A RothblattSold 8,000 sharesTotal: $1.73 M ($216.01/share)Martine A RothblattSold 8,000 sharesTotal: $1.79 M ($223.96/share)Martine A RothblattSold 8,000 sharesTotal: $1.74 M ($217.91/share)Paul A MahonSold 6,000 sharesTotal: $1.29 M ($214.39/share)Victory Capital Management Inc.Bought 7,046 shares on 3/10/2023Ownership: 0.062%View All Insider TransactionsView All Institutional Transactions UTHR Stock - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 2 sell ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price forecast for 2023? 10 Wall Street research analysts have issued twelve-month price objectives for United Therapeutics' shares. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they predict the company's stock price to reach $291.55 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2023? United Therapeutics' stock was trading at $278.09 at the beginning of the year. Since then, UTHR shares have decreased by 21.6% and is now trading at $218.01. View the best growth stocks for 2023 here. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) issued its quarterly earnings results on Wednesday, February, 22nd. The biotechnology company reported $2.67 EPS for the quarter, missing analysts' consensus estimates of $4.12 by $1.45. The biotechnology company had revenue of $491.50 million for the quarter, compared to analyst estimates of $519.20 million. United Therapeutics had a net margin of 37.56% and a trailing twelve-month return on equity of 16.30%. United Therapeutics's revenue was up 18.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.35 earnings per share. What ETFs hold United Therapeutics' stock? ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), First Trust Nasdaq Pharmaceuticals ETF (FTXH), First Trust US Equity Opportunities ETF (FPX), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Pharmaceuticals ETF (PJP), The Acquirers Fund (ZIG), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ) and Invesco DWA Healthcare Momentum ETF (PTH). What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). What is United Therapeutics' stock symbol? United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR." Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (6.29%), Renaissance Technologies LLC (5.14%), Avidity Partners Management LP (1.72%), Geode Capital Management LLC (1.45%), Assenagon Asset Management S.A. (1.32%) and Fuller & Thaler Asset Management Inc. (1.16%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is United Therapeutics' stock price today? One share of UTHR stock can currently be purchased for approximately $218.01. How much money does United Therapeutics make? United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.09 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $15.02 on an earnings per share basis. How many employees does United Therapeutics have? The company employs 965 workers across the globe. How can I contact United Therapeutics? United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291. This page (NASDAQ:UTHR) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.